137 related articles for article (PubMed ID: 4808651)
1. Determination of the blood concentrations of cyanate after intravenous administration to patients with sickle-cell disease.
Nigen AM; Peterson CM; Gillette PN; Manning JM
J Lab Clin Med; 1974 Jan; 83(1):139-46. PubMed ID: 4808651
[No Abstract] [Full Text] [Related]
2. Sodium cyanate as a potential treatment for sickle-cell disease.
Gillette PN; Peterson CM; Lu YS; Cerami A
N Engl J Med; 1974 Mar; 290(12):654-60. PubMed ID: 4813727
[No Abstract] [Full Text] [Related]
3. Gas chromatographic determination of the carbamylation of hemoglobin S by cyanate.
Manning JM; Lee CK; Cerami A; Gillette PN
J Lab Clin Med; 1973 Jun; 81(6):941-5. PubMed ID: 4710373
[No Abstract] [Full Text] [Related]
4. Clinical evaluation of cyanate in sickle cell anemia.
Harkness DR; Roth S
Prog Hematol; 1975; 9():157-84. PubMed ID: 766071
[No Abstract] [Full Text] [Related]
5. Bioavailability of sodium cyanate in patients with sickle cell disease and the lack of inhibition in vitro of globin synthesis at in vivo concentrations of cyanate.
Nigen AM; Manning JM; Peterson CM; White JM
J Pharmacol Exp Ther; 1975 Nov; 195(2):333-9. PubMed ID: 1185602
[TBL] [Abstract][Full Text] [Related]
6. Studies with intravenous sodium cyanate in patients with sickle cell anemia.
Peterson CM; Lu YS; Herbert JT; Cerami A; Gillette PN
J Pharmacol Exp Ther; 1974 Jun; 189(3):577-84. PubMed ID: 4602044
[No Abstract] [Full Text] [Related]
7. Preliminary studies of continuous extracorporeal carbamylation in the treatment of sickle cell anemia.
Balcerzak SP; Grever MR; Sing DE; Bishop JN; Segal ML
J Lab Clin Med; 1982 Sep; 100(3):345-55. PubMed ID: 7108349
[TBL] [Abstract][Full Text] [Related]
8. Cyanate as an inhibitor of red-cell sickling.
Cerami A
N Engl J Med; 1972 Oct; 287(16):807-12. PubMed ID: 4560520
[No Abstract] [Full Text] [Related]
9. The clinical use of cyanate in sickling.
Ranney HM
N Engl J Med; 1972 Jul; 287(2):98-100. PubMed ID: 4624186
[No Abstract] [Full Text] [Related]
10. The pharmacology of cyanate with a summary of its initial usage in sickle cell disease.
Gillette PN; Lu YS; Peterson CM
Prog Hematol; 1973; 8():181-90. PubMed ID: 4788375
[No Abstract] [Full Text] [Related]
11. Therapy of sickle cell disease: an approach with sodium cyanate.
Peterson CM; Cerami A
Semin Hematol; 1974 Oct; 11(4):569-76. PubMed ID: 4213637
[No Abstract] [Full Text] [Related]
12. Effects of urea and cyanate on sickling in vitro.
Segel GB; Feig SA; Mentzer WC; McCaffrey RP; Wells R; Bunn HF; Shohet SB; Nathan DG
N Engl J Med; 1972 Jul; 287(2):59-64. PubMed ID: 5031386
[No Abstract] [Full Text] [Related]
13. An extracorporeal system that modifies hemoglobin in patients with sickle cell anemia.
Babb AL; Scribner BH; Uvelli DA; Fry DL; Agodoa LC
Artif Organs; 1979 Feb; 3(1):62-72. PubMed ID: 435126
[No Abstract] [Full Text] [Related]
14. Continuous extracorporeal chemotherapy of blood utilizing hemodialysis: potential for the treatment of sickle cell disease.
Kjellstrand CM; Shideman JR; Eaton JW
Trans Am Soc Artif Intern Organs; 1974; 20 B():574-8. PubMed ID: 4450307
[No Abstract] [Full Text] [Related]
15. Carbamylation of the chains of hemoglobin S by cyanate in vitro and in vivo.
Njikam N; Jones WM; Nigen AM; Gillette PN; Williams RC; Manning JM
J Biol Chem; 1973 Dec; 248(23):8052-6. PubMed ID: 4752945
[No Abstract] [Full Text] [Related]
16. Clinical studies of a continuous extracorporeal cyanate treatment system for patients with sickle cell disease.
Lee MY; Uvelli DA; Agodoa LC; Scribner BH; Finch CA; Babb AL
J Lab Clin Med; 1982 Sep; 100(3):334-44. PubMed ID: 7108348
[TBL] [Abstract][Full Text] [Related]
17. Cyanate and sickling.
Charache S; Diederich D
N Engl J Med; 1971 Nov; 285(20):1147. PubMed ID: 5095746
[No Abstract] [Full Text] [Related]
18. Extracorporeal treatment of blood with cyanate in primates: physiologic and toxicologic observations.
Papayannopoulou T; Finch CA; Stamatoyannopoulos G; Hlastala MP
J Lab Clin Med; 1974 Jul; 84(1):81-91. PubMed ID: 4833845
[No Abstract] [Full Text] [Related]
19. Carbamylation distributions in extracorporeal treatment of sickle cell anemia.
Uvelli DA; Agodoa LC; Babb AL
J Lab Clin Med; 1978 Jun; 91(6):939-47. PubMed ID: 650059
[TBL] [Abstract][Full Text] [Related]
20. Sodium cyanate: chemical properties relevant to sickle cell disease therapy.
Labbe RF
J Pharm Sci; 1973 Oct; 62(10):1727-9. PubMed ID: 4752126
[No Abstract] [Full Text] [Related]
[Next] [New Search]
